<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:oboInOwl="http://www.geneontology.org/formats/oboInOwl#" xmlns:NCBITaxon="http://purl.obolibrary.org/obo/NCBITaxon#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:obo="http://purl.obolibrary.org/obo/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:ncbitaxon="http://purl.obolibrary.org/obo/ncbitaxon#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>                            NIH Public Access <br />                             Author Manuscript <br />                             J Neurosci. Author manuscript; available PMC 2013 October 10. <br />                            Published final edited form as: <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                             J Neurosci. 2013 April 10; 33(15): 6557&#8211;6562. doi:10.1523/JNEUROSCI.1536-12.2013. <br />  <br />  <br />  <br />                            The neuroprotective drug riluzole acts small conductance <br />                            Ca2+-activated K+ channels ameliorate defects Spinal <br />                            Muscular Atrophy models <br />                            Maria Dimitriadi1, Min Jeong Kye2,3, Geetika Kalloo1, Jill M. Yersak1, Mustafa Sahin2, and <br />                            Anne C. Hart1 <br />                            1Department Neuroscience, Brown University, Providence, RI 02912, USA <br />  <br />                            2The F.M. Kirby Neurobiology Center, Department Neurology, Children&#8217;s Hospital Boston, <br />                            Harvard Medical School, Boston, MA 02115, USA <br />                            3Institute   Human Genetics, University Cologne, Cologne, D-50931, Germany <br />  <br />                            Abstract <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                 Spinal muscular atrophy (SMA), recessive neuromuscular disorder, caused diminished <br />                                 function Survival Motor Neuron (SMN) protein. To define cellular processes pertinent <br />                                 SMA, parallel genetic screens undertaken Drosophila C. elegans SMA models to <br />                                 identify modifiers SMN loss function phenotypes. One <span id='am-21' about='obo:NCBITaxon_class' typeof='owl:Thing NCBITaxon:_taxonomic_rank'><span id='am-22' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-23' property="rdfs:label" content="class" datatype="xsd:string"></span>class</span> genetic modifiers <br />                                 small conductance, Ca2+-activated K+ (SK) channels. SK channels allow efflux of <br />                                 potassium ions intracellular calcium increases activated neuroprotective <br />                                 drug riluzole. The drug proven, albeit modest, efficacy treatment of <br />                                 Amyotrophic Lateral Sclerosis (ALS). It unclear riluzole extend lifespan ameliorate <br />                                 symptoms SMA patients previous studies limited insufficient power draw any <br />                                 conclusions. The critical biochemical target riluzole motorneuron disease known, but <br />                                 pharmacological targets riluzole include SK channels. We examine impact of <br />                                 riluzole different SMA models. In vertebrate neurons, riluzole treatment restored axon <br />                                 outgrowth caused diminished SMN. Additionally, riluzole ameliorated neuromuscular <br />                                 defects C. elegans SMA model SK channel function required beneficial <br />                                 effect. We propose riluzole improves motorneuron function acting SK channels and <br />                                 suggest SK channels important therapeutic targets SMA patients. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                            Introduction <br />                                             Spinal Muscular Atrophy (SMA), autosomal recessive neuromuscular disorder, the <br />                                             leading genetic cause infant death United States (Crawford &amp; Pardo, 1996; Pearn, <br />                                             1978). SMA primarily affects &#945;-motorneurons anterior horn spinal cord and <br />                                             characterized progressive muscle degeneration, loss neuromuscular function, <br />                                             paralysis and/or death. SMA caused Survival Motor Neuron 1 (SMN1) homozygous <br />                                             loss function mutations lead decreased Survival Motor Neuron (SMN) protein <br />                                             levels (Lefebvre et al., 1995). Amyotrophic Lateral Sclerosis (ALS) commonalities with <br />                                             SMA target spinal cord motorneurons share phenotypic, genetic molecular <br />                                             similarities. For example, SMN gene variants associated sporadic ALS <br />                                             (Blauw et al., 2012; <span id='am-37' about='obo:NCBITaxon_1276247' typeof='owl:Thing obo:NCBITaxon_33340 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_33154 obo:NCBITaxon_35567 obo:NCBITaxon_35568 obo:NCBITaxon_1276497 obo:NCBITaxon_33354 obo:NCBITaxon_33317 obo:NCBITaxon_2759 obo:NCBITaxon_6960 obo:NCBITaxon_7524 obo:NCBITaxon_6072 obo:NCBITaxon_33356 obo:NCBITaxon_33208 obo:NCBITaxon_33351 obo:NCBITaxon_72515 obo:NCBITaxon_85512 obo:NCBITaxon_197562 obo:NCBITaxon_197563 obo:NCBITaxon_27479 obo:NCBITaxon_6656 obo:NCBITaxon_7496 obo:NCBITaxon_33349 obo:NCBITaxon_1206794 obo:NCBITaxon_88770 obo:NCBITaxon_33345 obo:NCBITaxon_33347 obo:NCBITaxon_33342 obo:NCBITaxon_50557 obo:NCBITaxon_33343'><span id='am-38' property="rdfs:label" content="Corcia" datatype="xsd:string"></span><span id='am-39' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-40'  ></span><span id='am-41' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>Corcia</span> et al., 2009; Veldink et al., 2001), over-expression TDP-43, an <br />                                             ALS protein, increases SMN mRNA levels (Bose et al., 2008), mutation vesicle- <br />  <br />  <br />                            Corresponding author: Anne C. Hart, Brown University, 185 Meeting Street, Mailbox GL-N, Providence, RI 02912, <br />                            anne_hart@brown.edu. <br />                             Dimitriadi et al.                                                                                              Page 2 <br />  <br />  <br />                                                trafficking protein VAPB cause late-onset SMA ALS (Nishimura et al., 2004). <br />                                                Therefore, neuromuscular disorders share common neurodegenerative pathway <br />                                                respond similar treatments. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                We previously reported small conductance Ca2+-activated K+ (SK) channels are <br />                                                cross-<span id='am-34' about='obo:NCBITaxon_species' typeof='owl:Thing NCBITaxon:_taxonomic_rank'><span id='am-35' property="rdfs:label" content="species" datatype="xsd:string"></span><span id='am-36' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>species</span> invertebrate SMN modifiers (Chang et al., 2008; Dimitriadi et al., 2010). SK <br />                                                channels activated intracellular calcium, potassium selective, been <br />                                                implicated epilepsy, ataxias disorders (Pedarzani &amp; Stocker, 2008), play <br />                                                roles after-hyperpolarization, repetitive firing, dendritic integration, synaptic transmission <br />                                                synaptic plasticity (Keen et al., 1999; Schumacher et al., 2001; Xia et al., 1998). In <br />                                                neurons, SK channel activity regulated calcium entry voltage-gated calcium <br />                                                channels. The overall impact SK channels neuronal activity difficult predict. <br />                                                Increased potassium efflux reduce excitability, coupled depolarization- <br />                                                induced calcium influx, SK channels increase firing rates accelerating repolarization. <br />                                                SK2 channels complex L-type Ca2+ channels &#945;-actinin, an <br />                                                actin-binding protein (Lu et al., 2009; Lu et al., 2007). &#945;-actinin interacts directly SMN <br />                                                Drosophila adult muscle (Rajendra et al., 2007), &#945;-actinin orthologs invertebrate <br />                                                SMN modifier genes (Chang et al., 2008; Dimitriadi et al., 2010). <br />  <br />                                                SK channels pharmacological targets riluzole. Riluzole ameliorates the <br />                                                aberrant cytoskeletal organization synaptic terminals mice lacking SMN exon 7 <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                (Haddad et al., 2003). Riluzole impact severely affected SMA patients short <br />                                                duration study limited number subjects (Russman et al., 2003). <span id='am-24' about='obo:NCBITaxon_169495' typeof='owl:Thing obo:NCBITaxon_33340 obo:NCBITaxon_33213 obo:NCBITaxon_169440 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_7147 obo:NCBITaxon_43733 obo:NCBITaxon_33154 obo:NCBITaxon_43738 obo:NCBITaxon_480117 obo:NCBITaxon_33317 obo:NCBITaxon_169449 obo:NCBITaxon_480118 obo:NCBITaxon_2759 obo:NCBITaxon_6072 obo:NCBITaxon_6960 obo:NCBITaxon_43750 obo:NCBITaxon_33208 obo:NCBITaxon_85512 obo:NCBITaxon_197562 obo:NCBITaxon_197563 obo:NCBITaxon_7203 obo:NCBITaxon_6656 obo:NCBITaxon_7496 obo:NCBITaxon_1206794 obo:NCBITaxon_88770 obo:NCBITaxon_33392 obo:NCBITaxon_169455 obo:NCBITaxon_50557 obo:NCBITaxon_43741'><span id='am-25' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-26' property="rdfs:label" content="This" datatype="xsd:string"></span><span id='am-27' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-28'  ></span>This</span> study of <br />                                                insufficient power determine riluzole benefit SMA patient populations. <br />                                                Elucidating biochemical target riluzole increase understanding ALS and <br />                                                SMA pathogenesis. Here, test hypothesis riluzole ameliorate SMN loss of <br />                                                function defects species. <br />  <br />                                Materials Methods <br />                                C. elegans strains <br />                                                LM99 smn-1(ok355)I/hT2 (I;III) (Briese et al., 2009), HA2207 kcnl-2(tm1885) <br />                                                smn-1(ok355)/hT2, HA2415 kcnl-2(ok2818) smn-1(ok355)/hT2, HA2400 smn-1(ok355)/ <br />                                                hT2; slo-1(js118)V, HA2402 smn-1(ok355)/hT2; slo-2(nf100)X, HA2404 smn-1(ok355)/ <br />                                                hT2; sup-9(n180)II strains cultivated 20&#176;C standard conditions (Brenner, <br />                                                1974). kcnl-2 alleles tm1885 ok2818 backcrossed times, respectively. <br />                                                tm1885 removes transmembrane domains; ok2818 perturbs transmembrane domains <br />                                                calmodulin-binding domain. kcnl-2(tm1885) pumping rates slightly lower than <br />                                                kcnl-2(ok2818) (p=3&#215;10&#8722;4). All assays used progeny hT2 parents control genetic <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                background. <br />  <br />                                C. elegans assays <br />                                                The pharyngeal pumping assay performed previously described (Dimitriadi et al., <br />                                                2010). Eggs hatched L4440 control vector (Kamath &amp; Ahringer, 2003) reared at <br />                                                days 25&#176;C day 20&#176;C. Pumping rates determined larval <br />                                                stage. Average pumping rates (&#177; standard error mean, SEM) derived at <br />                                                independent trials (n&#8805; 25 animals total). Experimenters blinded to <br />                                                genotype/treatment trial. For Figure 2A 2C, independent <br />                                                trials performed pooled final figure. Unpooled results Figure <br />                                                2A: Trials 1&#8211;3 Control/DMSO 302&#177;7, Control/3&#956;M 266&#177;17, Control/33&#956;M 242&#177;12, <br />                                                Cesmn-1/DMSO 23&#177;5, Cesmn-1/3&#956;M 59&#177;14, Cesmn-1/33&#956;M 70&#177;13; Cesmn-1/DMSO vs <br />                                                Cesmn-1/3&#956;M p=0.04 &amp; Cesmn-1/DMSO vs Cesmn-1/33uM p=0.007; Trials 4&#8211;5 Control/ <br />  <br />  <br />                                                     J Neurosci. Author manuscript; available PMC 2013 October 10. <br />                             Dimitriadi et al.                                                                                        Page 3 <br />  <br />  <br />                                                DMSO 268&#177;9, Control/1&#956;M 257&#177;9, Cesmn-1/DMSO 48&#177;11, Cesmn-1/1&#956;M 38&#177;11. <br />                                                Unpooled results Figure 2C: Trials 1&#8211;4 Control 244&#177;6, kcnl-2(tm1885) 194&#177;13, Cesmn-1 <br />                                                57&#177;10, kcnl-2(tm1885) Cesmn-1 24&#177;8; p=0.01 Cesmn-1 vs kcnl-2(tm1885) Cesmn-1; Trials <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                5&#8211;7 Control 238&#177;7, kcnl-2(ok2818) 210&#177;12, Cesmn-1 74&#177;14, kcnl-2(ok2818) Cesmn-1 <br />                                                36&#177;10; p=0.01 Cesmn-1 vs kcnl-2(ok2818) Cesmn-1; Trials 8&#8211;10 Control 224&#177;9, slo-1 <br />                                                195&#177;13, slo-2 217&#177;11, sup-9 238&#177;11, Cesmn-1 47&#177;11, Cesmn-1;slo-1 51&#177;8, Cesmn-1;slo-2 <br />                                                74&#177;11, Cesmn-1;sup-9 62&#177;11; p=0.04 Cesmn-1 vs Cesmn-1;slo-2. The motility assay was <br />                                                described previously (Briese et al., 2009). Here, C. elegans reared plates two <br />                                                days 25&#176;C day 20&#176;C. Motility assessed manually 2 min M9 buffer <br />                                                Day 3 post-hatching regardless developmental stage. A complete bend mid-body was <br />                                                scored beat. At independent trials performed. <br />  <br />                                Compounds <br />                                                Riluzole (R116) apamin (A9459) purchased Sigma-Aldrich. Riluzole <br />                                                dramatically decreased egg laying (<span id='am-53' about='obo:NCBITaxon_1369087' typeof='obo:NCBITaxon_37567 owl:Thing obo:NCBITaxon_33340 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_85604 obo:NCBITaxon_104431 obo:NCBITaxon_33154 obo:NCBITaxon_37570 obo:NCBITaxon_41191 obo:NCBITaxon_33317 obo:NCBITaxon_2759 obo:NCBITaxon_6072 obo:NCBITaxon_6960 obo:NCBITaxon_33208 obo:NCBITaxon_41196 obo:NCBITaxon_197562 obo:NCBITaxon_85512 obo:NCBITaxon_197563 obo:NCBITaxon_95182 obo:NCBITaxon_41197 obo:NCBITaxon_6656 obo:NCBITaxon_7496 obo:NCBITaxon_7088 obo:NCBITaxon_1206794 obo:NCBITaxon_88770 obo:NCBITaxon_7100 obo:NCBITaxon_33392 obo:NCBITaxon_50557'><span id='am-54' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-55' property="rdfs:label" content="Data" datatype="xsd:string"></span><span id='am-56' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-57'  ></span>data</span> shown). <br />  <br />                                Hippocampal cell culture <br />                                                Experimental procedures performed compliance animal protocols approved by <br />                                                Children&#8217;s Hospital IACUC, Boston. Hippocampi dissected E18 Sprague-Dawley <br />                                                rat embryos (Charles River). Neurons dissociated papain, triturated, plated <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                poly-D-Lysine/Laminin (Sigma/Invitrogen) coated plates 250,000 cells/6-well <br />                                                culture plates Western blotting 20,000 cells/24-well culture plates for <br />                                                immunostaining. Neurons cultured Neurobasal medium B27 supplement <br />                                                (Invitrogen), 500&#956;M L-glutamine (Invitrogen), 1x penicillin/streptomycin (Invitrogen) at <br />                                                37&#176;C humidified incubator 5% CO2. <br />  <br />                                Inhibition SMN, riluzole treatment measurement neuronal morphology SMN <br />                                                knocked-down using conventional siRNA technique, (Applied Biosystems), <br />                                                Lipofectamine 2000 (Invitrogen), Opti-MEM (Invitrogen). Briefly, neurons were <br />                                                transiently transfected siRNA treated riluzole DMSO 24 hours. Four <br />                                                days post-transfection, protein lysates collected; SMN (BD Biosciences) and <br />                                                synaptophysin (Cell Signaling) protein levels measured Western using GAPDH <br />                                                (Life Technologies) control. For immunohistology, neurons fixed 4% <br />                                                paraformaldehyde stained Tau antibody (Millipore) (Choi et al., 2008). Length of <br />                                                Tau-positive axons measured using ImageJ. <br />  <br />                                Statistical analysis <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                Significance determined Mann-Whitney U (two-tailed) one-way ANOVA. After <br />                                                ANOVA, paired t-tests used identify significantly different pairs. Corresponding p <br />                                                F values reported. <br />  <br />                                Results <br />                                Riluzole prevents axonal defects vertebrate neurons <br />                                                We examined impact riluzole rat embryonic hippocampal neurons reduced <br />                                                SMN levels. SMN knockdown reduced axon outgrowth neurons based overall <br />                                                process length (p=6.7&#215;10&#8722;5). Treatment 10nM 50nM riluzole increased control and <br />                                                restored SMN-deficient axons comparable levels (Figure 1A &amp; 1B). Longest axon length <br />                                                significantly reduced SMN knockdown (p=1.4&#215;10&#8722;5), restored wild <br />                                                type levels riluzole treatment (Figure 1C). Riluzole does ameliorate SMN <br />                                                knockdown defects increasing SMN protein levels; riluzole treatment actually decreased <br />  <br />  <br />                                                     J Neurosci. Author manuscript; available PMC 2013 October 10. <br />                             Dimitriadi et al.                                                                                            Page 4 <br />  <br />  <br />                                                SMN protein levels control SMN deficient neurons (Figure 1D). SMN protein <br />                                                levels tightly regulated development; expression high embryonic tissues, but <br />                                                concentration SMN decreases cells differentiate (Grice &amp; Liu, 2011; La Bella et al., <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                1998). To address possibility riluzole accelerate hippocampal neuron <br />                                                maturation, lowering SMN, examined synaptophysin levels (which normally <br />                                                increase hippocampal neurons mature culture) (Daly &amp; Ziff, 1997). Riluzole raised <br />                                                synaptophysin levels consistent accelerated maturation (Figure 1E). Therefore, the <br />                                                riluzole neuroprotection increased SMN levels, riluzole accelerate <br />                                                neuronal maturation. <br />  <br />                                Riluzole ameliorates SMN loss function defects C. elegans <br />                                                To address mechanism riluzole protection, turned <span id='am-9' about='obo:NCBITaxon_6239' typeof='owl:Thing obo:NCBITaxon_33208 obo:NCBITaxon_119089 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_55879 obo:NCBITaxon_131567 obo:NCBITaxon_55885 obo:NCBITaxon_6237 obo:NCBITaxon_6236 obo:NCBITaxon_33154 obo:NCBITaxon_6231 obo:NCBITaxon_1206794 obo:NCBITaxon_33317 obo:NCBITaxon_2759 obo:NCBITaxon_6243 obo:NCBITaxon_6072'><span id='am-10' property="oboInOwl:hasRelatedSynonym" content="Rhabditis elegans" datatype="xsd:string"></span><span id='am-11' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-12' property="oboInOwl:hasExactSynonym" content="roundworm" datatype="xsd:string"></span><span id='am-13'  ></span><span id='am-14' property="rdfs:label" content="Caenorhabditis elegans" datatype="xsd:string"></span><span id='am-15' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>Caenorhabditis elegans</span> <br />                                                SMA model. The C. elegans genome harbors single ortholog SMN, smn-1, referred to <br />                                                Cesmn-1 clarity. Complete loss Cesmn-1 causes slow growth, larval lethality <br />                                                impairs neuromuscular function locomotion pharyngeal pumping during <br />                                                feeding (Briese et al, 2009; Dimitriadi et al., 2010). C. elegans feed microorganisms <br />                                                using discrete subset muscles neurons pharynx (Avery, 1993). Animals pump <br />                                                continuously 250 beats minute food. The pumping rates SMN loss of <br />                                                function animals (Cesmn-1(lf)) significantly reduced; defects progressive and <br />                                                developmental defect. Cesmn-1(lf) recessive heterozygous animals overtly <br />                                                normal (Briese et al, 2009; Dimitriadi et al., 2010). To assess impact riluzole, control <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                Cesmn-1(lf) animals reared plates containing drug. Riluzole partially <br />                                                rescued SMN loss function defects treatment increased Cesmn-1(lf) pharyngeal <br />                                                pumping rates (p=0.044 3&#956;M, p=0.004 33&#956;M, Figure 2A). By contrast, riluzole <br />                                                lowered pumping rates controls, (p=0.027 1&#956;M, p=0.001 33&#956;M) suggesting <br />                                                riluzole beneficial neuromuscular function perturbed. The efficacy of <br />                                                riluzole tested using motility, neuromuscular assay measures frequency <br />                                                body bends swimming (Briese et al., 2009). Riluzole significantly increased the <br />                                                Cesmn-1(lf) motility (p=0.04 333M, Figure 2D) consistent riluzole ameliorating <br />                                                Cesmn-1 loss function neuromuscular defects. <br />  <br />                                Riluzole likely acts SK channels <br />                                                We tested hypothesis riluzole acts SK channels ameliorate defects using C. <br />                                                elegans. First, SK channels blocked pharmacologically. Application SK2/SK3 <br />                                                channel blocker apamin exacerbated Cesmn-1(lf) pumping defects, suggesting blocking <br />                                                SK channels impairs Cesmn-1(lf) neuromuscular function (Figure 2B). Second, SK <br />                                                channels tested using genetic tools. Previously, RNAi knockdown C. elegans SK <br />                                                channel ortholog (kcnl-2) enhanced Cesmn-1(lf) growth defects ameliorated their <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                pumping defects (Dimitriadi et al., 2010). As RNAi off-target effects RNAi by <br />                                                feeding inefficient C. elegans neurons, used C. elegans kcnl-2 alleles <br />                                                (kcnl-2(tm1885) kcnl-2(ok2818)) likely cause complete loss function, to <br />                                                accurately assess impact kcnl-2 loss Cesmn-1. Pumping rates kcnl-2(tm1885) <br />                                                Cesmn-1(lf) kcnl-2(ok2818) Cesmn-1(lf) double mutant animals significantly <br />                                                decreased (p=0.003 &amp; p=0.023, respectively, Figure 2C). If riluzole activates SK channels to <br />                                                ameliorate SMN loss function defects, loss kcnl-2 abrogate beneficial <br />                                                effects riluzole. Consistent hypothesis, riluzole treatment did increase the <br />                                                pumping rates kcnl-2 Cesmn-1(lf) mutant animals (Figure 2C tm1885; data shown <br />                                                ok2818). Therefore, riluzole requires kcnl-2 SK channel function ameliorate SMN <br />                                                loss function neuromuscular defects. We confirmed assay. kcnl-2(tm1885) <br />                                                Cesmn-1(lf) animals decreased motility swimming compared controls <br />                                                (p=0.029 &amp; p=0.007, respectively). Loss kcnl-2 exacerbated motility defects of <br />                                                Cesmn-1(lf) (p=0.001), riluzole treatment did benefit kcnl-2 Cesmn-1(lf) mutant <br />  <br />  <br />                                                     J Neurosci. Author manuscript; available PMC 2013 October 10. <br />                             Dimitriadi et al.                                                                                             Page 5 <br />  <br />  <br />                                                animals (Figure 2D tm1885; data shown ok2818). To address specificity kcnl-2, <br />                                                potassium channels examined. Loss slo-1(js118), slo-2(nf100) sup-9(n180) <br />                                                did exacerbate Cesmn-1(lf) pumping defects, suggesting riluzole requires kcnl-2 SK <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                channels ameliorate SMN loss function neuromuscular defects. <br />  <br />                                Discussion <br />                                                The early observations abnormal glutamate metabolism decreased glutamate <br />                                                transport brain spinal cord ALS patients led hypothesis the <br />                                                excitatory amino acid neurotransmitter glutamate involved ALS pathogenesis <br />                                                (Plaitakis, 1991; Rothstein et al., 1992). Hence, drugs affecting glutamatergic system <br />                                                suggested putative therapeutic agents. Riluzole initially identified paralytic <br />                                                agent (Domino et al., 1952) later shown indirectly modulate glutamatergic <br />                                                transmission (Albo et al., 2004; Benavides et al., 1985; Debono et al., 1993; Doble et al., <br />                                                1992). It subsequently significantly improve muscle strength disease <br />                                                progression ALS patients (Bensimon et al., 1994; Lacomblez et al., 1996). The <br />                                                mechanism riluzole protection remains unclear (Bellingham, 2011; Kuo et al., 2005; <br />                                                Schuster et al., 2012), riluzole diverse direct targets. These include potassium <br />                                                channels: SK channels (Cao et al., 2002; Grunnet et al., 2001), large conductance Ca2+- <br />                                                activated BK channels (Wang et al., 2008; Wu &amp; Li, 1999), TREK-1 TRAAK two- <br />                                                pore-domain channels (Duprat et al., 2000; Fink et al., 1998). Also, riluzole blocks voltage- <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                dependent sodium channels (Benoit &amp; Escande, 1991; Song et al., 1997; Zona et al., 1998) <br />                                                voltage-gated N- P/Q-type calcium channels (Huang et al., 1997). Additionally, <br />                                                riluzole inhibit cholinergic receptors (Deflorio et al., 2012) decrease protein kinase <br />                                                C (PKC) activity (Noh et al., 2000). <br />  <br />                                                SK channels identified previously cross-species genetic modifiers invertebrate <br />                                                SMA models (Chang et al., 2008; Dimitriadi et al., 2010). Here, provide evidence that <br />                                                riluzole beneficial effects SMA models act SK channels. Loss the <br />                                                C. elegans SK channel ortholog kcnl-2 exacerbated Cesmn-1(lf) neuromuscular defects. <br />                                                Apamin, blocks SK2 SK3 channels, exacerbated Cesmn-1 loss function <br />                                                defects. Treatment riluzole, actions include SK channel activation, improved the <br />                                                neuromuscular function Cesmn-1(lf) animals axon outgrowth SMN deprived <br />                                                rat hippocampal neurons. <br />  <br />                                                Although Franks co-workers identified sodium current pharyngeal muscles is <br />                                                sensitive sodium channel drugs (Franks et al., 2002), genes mRNAs encoding <br />                                                classical voltage-gated sodium channels C. elegans, suggesting that <br />                                                riluzole likely does act channels ameliorate Cesmn-1(lf) defects. Riluzole <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                restored axon outgrowth caused diminished SMN vertebrate neurons. Apamin, <br />                                                blocks classes SK channels, impact hippocampal neurons (data not <br />                                                shown), suggesting apamin-sensitive SK channels expressed stage <br />                                                beneficial effects riluzole solely SK channels mammalian <br />                                                neurons. <br />  <br />                                                The present study reports riluzole, beneficial, does increase SMN protein <br />                                                levels. However, riluzole treatment increased levels hippocampal neuron maturation <br />                                                marker, synaptophysin, suggesting riluzole accelerate maturation consequent <br />                                                decreases SMN levels. Therefore, worthwhile investigate synergistic <br />                                                effects riluzole combination drugs directly increase SMN levels (Wadman et <br />                                                al., 2011a; Wadman et al., 2011b). In summary, studies demonstrate beneficial <br />                                                impact riluzole SMA models suggest riluzole acts SK channels to <br />  <br />  <br />  <br />                                                     J Neurosci. Author manuscript; available PMC 2013 October 10. <br />                             Dimitriadi et al.                                                                                                              Page 6 <br />  <br />  <br />                                                ameliorate SMN loss function defects, delineating important therapeutic pathway for <br />                                                neuromuscular disease patients. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                Acknowledgments <br />                                                This work supported funding SMA Foundation NIH NINDS (NS066888) A.C.H, Slaney <br />                                                <span id='am-6' about='obo:NCBITaxon_family' typeof='owl:Thing NCBITaxon:_taxonomic_rank'><span id='am-7' property="rdfs:label" content="family" datatype="xsd:string"></span><span id='am-8' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>Family</span> Fund Children&#8217;s Hospital Boston Translational Research Program M.S., Children&#8217;s Hospital <br />                                                Boston Mental Retardation Developmental Disabilities Research Center (P30 HD18655). M.K. supported by <br />                                                fellowship William Hearst Foundation. Some nematode strains used work provided the <br />                                                <span id='am-16' about='obo:NCBITaxon_6237' typeof='owl:Thing obo:NCBITaxon_33208 obo:NCBITaxon_119089 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_55879 obo:NCBITaxon_131567 obo:NCBITaxon_55885 obo:NCBITaxon_6236 obo:NCBITaxon_33154 obo:NCBITaxon_6231 obo:NCBITaxon_1206794 obo:NCBITaxon_33317 obo:NCBITaxon_2759 obo:NCBITaxon_6243 obo:NCBITaxon_6072'><span id='am-17'  ></span><span id='am-18' property="rdfs:label" content="Caenorhabditis" datatype="xsd:string"></span><span id='am-19' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-20' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span>Caenorhabditis</span> Genetics Center, funded NIH National Center Research Resources. Helpful <br />                                                discussions Drs. Spyros Artavanis-Tsakonas, David Van Vactor, Lee Rubin, Diane Lipscombe, members <br />                                                laboratories invaluable. We grateful C. elegans knockout consortia Japanese National <br />                                                BioResource Project reagents, Luis Miguel Briseno help measurement neuronal morphology <br />                                                Dr. George Poulogiannis statistical analysis. <br />  <br />  <br />                                References <br />                                                Albo F, Pieri M, Zona C. Modulation AMPA receptors spinal motorneurons the <br />                                                  neuroprotective agent riluzole. J Neurosci Res. 2004; 78:200&#8211;7. [PubMed: 15378511] <br />                                                Avery L. The genetics feeding Caenorhabditis elegans. Genetics. 1993; 133:897&#8211;917. [PubMed: <br />                                                  8462849] <br />                                                Bellingham MC. A review neural mechanisms action clinical efficiency riluzole in <br />                                                  treating amyotrophic lateral sclerosis: learned decade? CNS Neurosci Ther. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                  2011; 17:4&#8211;31. [PubMed: 20236142] <br />                                                Benavides J, Camelin JC, Mitrani N, Flamand F, Uzan A, Legrand JJ, Gueremy C, Le Fur G. 2- <br />                                                  Amino-6-trifluoromethoxy benzothiazole, possible antagonist excitatory amino acid <br />                                                  neurotransmission--II. Biochemical properties. Neuropharmacology. 1985; 24:1085&#8211;92. [PubMed: <br />                                                  3001571] <br />                                                Benoit E, Escande D. Riluzole specifically blocks inactivated Na channels myelinated nerve fibre. <br />                                                  Pflugers Arch. 1991; 419:603&#8211;9. [PubMed: 1664937] <br />                                                Bensimon G, Lacomblez L, Meininger V. A controlled trial riluzole amyotrophic lateral sclerosis. <br />                                                  ALS/Riluzole Study Group. N Engl J Med. 1994; 330:585&#8211;91. [PubMed: 8302340] <br />                                                Blauw HM, Barnes CP, van Vught PW, van Rheenen W, Verheul M, Cuppen E, Veldink JH, van den <br />                                                  Berg LH. SMN1 gene duplications associated sporadic ALS. Neurology. 2012; 78:776&#8211;80. <br />                                                  [PubMed: 22323753] <br />                                                Bose JK, Wang IF, Hung L, Tarn WY, Shen CK. TDP-43 overexpression enhances exon 7 inclusion <br />                                                  survival motor neuron pre-mRNA splicing. J Biol Chem. 2008; 283:28852&#8211;9. <br />                                                  [PubMed: 18703504] <br />                                                Brenner S. The genetics Caenorhabditis elegans. Genetics. 1974; 77:71&#8211;94. [PubMed: 4366476] <br />                                                Briese M, Esmaeili B, Fraboulet S, Burt EC, Christodoulou S, Towers PR, Davies KE, Sattelle DB. <br />                                                    Deletion smn-1, Caenorhabditis elegans ortholog spinal muscular atrophy gene, <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                    results locomotor dysfunction reduced lifespan. Hum Mol Genet. 2009; 18:97&#8211;104. <br />                                                    [PubMed: 18829666] <br />                                                Cao YJ, Dreixler JC, Couey JJ, Houamed KM. Modulation recombinant native neuronal SK <br />                                                    channels neuroprotective drug riluzole. Eur J Pharmacol. 2002; 449:47&#8211;54. [PubMed: <br />                                                    12163105] <br />                                                Chang HC, Dimlich DN, Yokokura T, Mukherjee A, Kankel MW, Sen A, Sridhar V, Fulga TA, Hart <br />                                                    AC, Van Vactor D, Artavanis-Tsakonas S. Modeling spinal muscular atrophy Drosophila. PLoS <br />                                                    One. 2008; 3:e3209. [PubMed: 18791638] <br />                                                Choi YJ, Di Nardo A, Kramvis I, Meikle L, Kwiatkowski DJ, Sahin M, He X. Tuberous sclerosis <br />                                                    complex proteins control axon formation. Genes Dev. 2008; 22:2485&#8211;95. [PubMed: 18794346] <br />                                                Corcia P, Camu W, Praline J, Gordon PH, Vourch P, Andres C. The importance SMN genes in <br />                                                    genetics sporadic ALS. Amyotroph Lateral Scler. 2009; 10:436&#8211;40. [PubMed: 19922137] <br />                                                Crawford TO, Pardo CA. The neurobiology childhood spinal muscular atrophy. Neurobiol Dis. <br />                                                    1996; 3:97&#8211;110. [PubMed: 9173917] <br />  <br />  <br />  <br />                                                      J Neurosci. Author manuscript; available PMC 2013 October 10. <br />                             Dimitriadi et al.                                                                                                   Page 7 <br />  <br />  <br />                                                Daly C, Ziff EB. Post-transcriptional regulation synaptic vesicle protein expression the <br />                                                    developmental control synaptic vesicle formation. J Neurosci. 1997; 17:2365&#8211;75. [PubMed: <br />                                                    9065497] <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                Debono MW, Le Guern J, Canton T, Doble A, Pradier L. Inhibition riluzole electrophysiological <br />                                                    responses mediated rat kainate NMDA receptors expressed Xenopus oocytes. Eur J <br />                                                    Pharmacol. 1993; 235:283&#8211;9. [PubMed: 7685290] <br />                                                Deflorio C, Palma E, Conti L, Roseti C, Manteca A, Giacomelli E, Catalano M, Limatola C, Inghilleri <br />                                                    M, Grassi F. Riluzole Blocks Human Muscle Acetylcholine Receptors. J Physiol. 2012; 590:2519&#8211; <br />                                                    28. [PubMed: 22431338] <br />                                                Dimitriadi M, Sleigh JN, Walker A, Chang HC, Sen A, Kalloo G, Harris J, Barsby T, Walsh MB, <br />                                                    Satterlee JS, Li C, Van Vactor D, Artavanis-Tsakonas S, Hart AC. Conserved genes act as <br />                                                    modifiers invertebrate SMN loss function defects. PLoS Genet. 2010; 6:e1001172. [PubMed: <br />                                                    21124729] <br />                                                Doble A, Hubert JP, Blanchard JC. Pertussis toxin pretreatment abolishes inhibitory effect of <br />                                                    riluzole carbachol D-[3H]aspartate release cultured cerebellar granule cells. Neurosci <br />                                                    Lett. 1992; 140:251&#8211;4. [PubMed: 1354343] <br />                                                Domino EF, Unna KR, Kerwin J. Pharmacological properties benzazoles. I. Relationship between <br />                                                    structure paralyzing action. J Pharmacol Exp Ther. 1952; 105:486&#8211;97. [PubMed: 14955779] <br />                                                Duprat F, Lesage F, Patel AJ, Fink M, Romey G, Lazdunski M. The neuroprotective agent riluzole <br />                                                    activates P domain K(+) channels TREK-1 TRAAK. Mol Pharmacol. 2000; 57:906&#8211; <br />                                                    12. [PubMed: 10779373] <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                Fink M, Lesage F, Duprat F, Heurteaux C, Reyes R, Fosset M, Lazdunski M. A neuronal P <br />                                                    domain K+ channel stimulated arachidonic acid polyunsaturated fatty acids. EMBO J. <br />                                                    1998; 17:3297&#8211;308. [PubMed: 9628867] <br />                                                Franks CJ, Pemberton D, Vinogradova I, Cook A, Walker RJ, Holden-Dye L. Ionic basis resting <br />                                                    membrane potential action potential pharyngeal muscle Caenorhabditis elegans. J <br />                                                    Neurophysiol. 2002; 87:954&#8211;61. [PubMed: 11826060] <br />                                                Grice SJ, Liu JL. Survival motor neuron protein regulates stem cell division, proliferation, and <br />                                                    differentiation Drosophila. PLoS Genet. 7:e1002030. [PubMed: 21490958] <br />                                                Grunnet M, Jespersen T, Angelo K, Frokjaer-Jensen C, Klaerke DA, Olesen SP, Jensen BS. <br />                                                    Pharmacological modulation SK3 channels. Neuropharmacology. 2001; 40:879&#8211;87. [PubMed: <br />                                                    11378158] <br />                                                Haddad H, Cifuentes-Diaz C, Miroglio A, Roblot N, Joshi V, Melki J. Riluzole attenuates spinal <br />                                                    muscular atrophy disease progression mouse model. Muscle Nerve. 2003; 28:432&#8211;7. <br />                                                    [PubMed: 14506714] <br />                                                Huang CS, Song JH, Nagata K, Yeh JZ, Narahashi T. Effects neuroprotective agent riluzole on <br />                                                    high voltage-activated calcium channels rat dorsal <span id='am-29' about='obo:NCBITaxon_1' typeof='owl:Thing'><span id='am-30' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-31' property="oboInOwl:hasRelatedSynonym" content="all" datatype="xsd:string"></span><span id='am-32' property="rdfs:label" content="root" datatype="xsd:string"></span><span id='am-33' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>root</span> ganglion neurons. J Pharmacol Exp <br />                                                    Ther. 1997; 282:1280&#8211;90. [PubMed: 9316836] <br />                                                Kamath RS, Ahringer J. Genome-wide RNAi screening Caenorhabditis elegans. Methods. 2003; <br />                                                    30:313&#8211;21. [PubMed: 12828945] <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                Keen JE, Khawaled R, Farrens DL, Neelands T, Rivard A, Bond CT, Janowsky A, Fakler B, Adelman <br />                                                    JP, Maylie J. Domains responsible constitutive Ca(2+)-dependent interactions between <br />                                                    calmodulin small conductance Ca(2+)-activated potassium channels. J Neurosci. 1999; <br />                                                    19:8830&#8211;8. [PubMed: 10516302] <br />                                                Kuo JJ, Siddique T, Fu R, Heckman CJ. Increased persistent Na(+) current effect on <br />                                                    excitability motoneurones cultured mutant SOD1 mice. J Physiol. 2005; 563:843&#8211;54. <br />                                                    [PubMed: 15649979] <br />                                                La Bella V, Cisterni C, Salaun D, Pettmann B. Survival motor neuron (SMN) protein rat is <br />                                                    expressed different molecular forms developmentally regulated. Eur J Neurosci. 1998; <br />                                                    10:2913&#8211;23. [PubMed: 9758161] <br />                                                Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study riluzole in <br />                                                    amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. <br />                                                    1996; 347:1425&#8211;31. [PubMed: 8676624] <br />  <br />  <br />  <br />  <br />                                                     J Neurosci. Author manuscript; available PMC 2013 October 10. <br />                             Dimitriadi et al.                                                                                                    Page 8 <br />  <br />  <br />                                                Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L, Benichou B, Cruaud C, <br />                                                    Millasseau P, Zeviani M, et al. Identification characterization spinal muscular atrophy- <br />                                                    determining gene. Cell. 1995; 80:155&#8211;65. [PubMed: 7813012] <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                Lu L, Timofeyev V, Li N, Rafizadeh S, Singapuri A, Harris TR, Chiamvimonvat N. Alpha-actinin2 <br />                                                    cytoskeletal protein required functional membrane localization Ca2+-activated K+ <br />                                                    channel (SK2 channel). Proc Natl Acad Sci U S A. 2009; 106:18402&#8211;7. [PubMed: 19815520] <br />                                                Lu L, Zhang Q, Timofeyev V, Zhang Z, Young JN, Shin HS, Knowlton <span id='am-42' about='obo:NCBITaxon_152839' typeof='owl:Thing obo:NCBITaxon_78536 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_4447 obo:NCBITaxon_4747 obo:NCBITaxon_158359 obo:NCBITaxon_158331 obo:NCBITaxon_3398 obo:NCBITaxon_1437183 obo:NCBITaxon_33090 obo:NCBITaxon_158350 obo:NCBITaxon_73496 obo:NCBITaxon_131221 obo:NCBITaxon_58024 obo:NCBITaxon_58023 obo:NCBITaxon_2759 obo:NCBITaxon_35493 obo:NCBITaxon_1437197 obo:NCBITaxon_3193'><span id='am-43' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-44' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-45'  ></span><span id='am-46' property="rdfs:label" content="Aa" datatype="xsd:string"></span><span id='am-47' property="oboInOwl:hasRelatedSynonym" content="Aa Rchb.f." datatype="xsd:string"></span>AA</span>, Chiamvimonvat N. <br />                                                    Molecular coupling Ca2+-activated K+ channel L-type Ca2+ channels alpha-actinin2. <br />                                                    Circ Res. 2007; 100:112&#8211;20. [PubMed: 17110593] <br />                                                Nishimura AL, Mitne-Neto M, Silva HC, Richieri-Costa A, Middleton S, Cascio D, Kok F, Oliveira <br />                                                    JR, Gillingwater T, Webb J, Skehel P, Zatz M. A mutation vesicle-trafficking protein VAPB <br />                                                    causes late-onset spinal muscular atrophy amyotrophic lateral sclerosis. Am J Hum Genet. <br />                                                    2004; 75:822&#8211;31. [PubMed: 15372378] <br />                                                Noh KM, Hwang JY, Shin HC, Koh JY. A novel neuroprotective mechanism riluzole: direct <br />                                                    inhibition protein kinase C. Neurobiol Dis. 2000; 7:375&#8211;83. [PubMed: 10964608] <br />                                                Pearn J. Incidence, prevalence, gene frequency studies chronic childhood spinal muscular <br />                                                    atrophy. J Med Genet. 1978; 15:409&#8211;13. [PubMed: 745211] <br />                                                Pedarzani P, Stocker M. Molecular cellular basis small--and intermediate-conductance, <br />                                                    calcium-activated potassium channel function brain. Cell Mol Life Sci. 2008; 65:3196&#8211;217. <br />                                                    [PubMed: 18597044] <br />                                                Plaitakis A. Altered glutamatergic mechanisms selective motor neuron degeneration in <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                    amyotrophic lateral sclerosis: possible role <span id='am-1' about='obo:NCBITaxon_3846' typeof='owl:Thing obo:NCBITaxon_78536 obo:NCBITaxon_3814 obo:NCBITaxon_1 obo:NCBITaxon_72025 obo:NCBITaxon_131567 obo:NCBITaxon_3803 obo:NCBITaxon_3398 obo:NCBITaxon_1437183 obo:NCBITaxon_33090 obo:NCBITaxon_163735 obo:NCBITaxon_91827 obo:NCBITaxon_131221 obo:NCBITaxon_71240 obo:NCBITaxon_58024 obo:NCBITaxon_1437201 obo:NCBITaxon_58023 obo:NCBITaxon_91835 obo:NCBITaxon_2759 obo:NCBITaxon_35493 obo:NCBITaxon_71275 obo:NCBITaxon_3193'><span id='am-2' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-3' property="rdfs:label" content="Glycine" datatype="xsd:string"></span><span id='am-4'  ></span><span id='am-5' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>glycine</span>. Adv Neurol. 1991; 56:319&#8211;26. [PubMed: <br />                                                    1677233] <br />                                                Rajendra TK, Gonsalvez GB, Walker MP, Shpargel KB, Salz HK, Matera AG. A Drosophila <br />                                                    <span id='am-48' about='obo:NCBITaxon_80614' typeof='owl:Thing obo:NCBITaxon_80611 obo:NCBITaxon_1 obo:NCBITaxon_5302 obo:NCBITaxon_131567 obo:NCBITaxon_4751 obo:NCBITaxon_33154 obo:NCBITaxon_452333 obo:NCBITaxon_5204 obo:NCBITaxon_451864 obo:NCBITaxon_68889 obo:NCBITaxon_155619 obo:NCBITaxon_2759'><span id='am-49' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-50' property="rdfs:label" content="Melanogaster" datatype="xsd:string"></span><span id='am-51'  ></span><span id='am-52' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span>melanogaster</span> model spinal muscular atrophy reveals function SMN striated muscle. J <br />                                                    Cell Biol. 2007; 176:831&#8211;41. [PubMed: 17353360] <br />                                                Rothstein JD, Martin LJ, Kuncl RW. Decreased glutamate transport brain spinal cord in <br />                                                    amyotrophic lateral sclerosis. N Engl J Med. 1992; 326:1464&#8211;8. [PubMed: 1349424] <br />                                                Russman BS, Iannaccone ST, Samaha FJ. A phase 1 trial riluzole spinal muscular atrophy. Arch <br />                                                    Neurol. 2003; 60:1601&#8211;3. [PubMed: 14623733] <br />                                                Schumacher MA, Rivard AF, Bachinger HP, Adelman JP. Structure gating domain Ca2+- <br />                                                    activated K+ channel complexed Ca2+/calmodulin. Nature. 2001; 410:1120&#8211;4. [PubMed: <br />                                                    11323678] <br />                                                Schuster JE, Fu R, Siddique T, Heckman CJ. Effect prolonged riluzole exposure cultured <br />                                                    motoneurons mouse model ALS. J Neurophysiol. 107:484&#8211;92. [PubMed: 22013234] <br />                                                Song JH, Huang CS, Nagata K, Yeh JZ, Narahashi T. Differential action riluzole tetrodotoxin- <br />                                                    sensitive tetrodotoxin-resistant sodium channels. J Pharmacol Exp Ther. 1997; 282:707&#8211;14. <br />                                                    [PubMed: 9262334] <br />                                                Veldink JH, van den Berg LH, Cobben JM, Stulp RP, De Jong JM, Vogels OJ, Baas F, Wokke JH, <br />                                                    Scheffer H. Homozygous deletion survival motor neuron 2 gene prognostic factor in <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                    sporadic ALS. Neurology. 2001; 56:749&#8211;52. [PubMed: 11274309] <br />                                                Wadman RI, Bosboom WM, van den Berg LH, Wokke JH, Iannaccone ST, Vrancken AF. Drug <br />                                                    treatment spinal muscular atrophy type I. Cochrane Database Syst Rev. 2011a; 12:CD006281. <br />                                                    [PubMed: 22161399] <br />                                                Wadman RI, Bosboom WM, van den Berg LH, Wokke JH, Iannaccone ST, Vrancken AF. Drug <br />                                                    treatment spinal muscular atrophy types II III. Cochrane Database Syst Rev. 2011b; <br />                                                    12:CD006282. [PubMed: 22161400] <br />                                                Wang YJ, Lin MW, Lin AA, Wu SN. Riluzole-induced block voltage-gated Na+ current and <br />                                                    activation BKCa channels cultured differentiated human skeletal muscle cells. Life Sci. 2008; <br />                                                    82:11&#8211;20. [PubMed: 18068197] <br />                                                Wu SN, Li HF. Characterization riluzole-induced stimulation large-conductance calcium- <br />                                                    activated potassium channels rat pituitary GH3 cells. J Investig Med. 1999; 47:484&#8211;95. <br />  <br />  <br />  <br />  <br />                                                     J Neurosci. Author manuscript; available PMC 2013 October 10. <br />                             Dimitriadi et al.                                                                                                 Page 9 <br />  <br />  <br />                                                Xia XM, Fakler B, Rivard A, Wayman G, Johnson-Pais T, Keen JE, Ishii T, Hirschberg B, Bond CT, <br />                                                    Lutsenko S, Maylie J, Adelman JP. Mechanism calcium gating small-conductance calcium- <br />                                                    activated potassium channels. Nature. 1998; 395:503&#8211;7. [PubMed: 9774106] <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                Zona C, Siniscalchi A, Mercuri NB, Bernardi G. Riluzole interacts voltage-activated sodium and <br />                                                    potassium currents cultured rat cortical neurons. Neuroscience. 1998; 85:931&#8211;8. [PubMed: <br />                                                    9639285] <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                     J Neurosci. Author manuscript; available PMC 2013 October 10. <br />                             Dimitriadi et al.                                                                                      Page 10 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                Figure 1. <br />              <br /> </body></html>